Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Trial Profile

A comparative double-blind controlled for the effect of fenofibrate treatment on the expression of genes of cholesterol homeostasis, inflammation and cell proliferation in carotid plaques asymptomatic arteriosclerosis. [Etude controlee comparative en double aveugle de l'effet d'un traitement par le fenofibrate sur l'expression des genes de l'homeostasie du cholesterol, de l'inflammation et de la proliferation cellulaire dans les plaques arterosclereuses carotidiennes asymptomatiques.]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fenofibrate (Primary)
  • Indications Atherosclerosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms FENOGEN

Most Recent Events

  • 29 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top